Тропонин I сверхчувствительный

High-sensitivity troponin I is used to confirm or exclude myocardial infarction in patients presenting with acute chest pain or other ischemic symptoms. It is frequently ordered with creatine kinase MB and myoglobin, but troponin I is more specific for myocardial injury and remains elevated longer, allowing assessment of injury magnitude and helping distinguish cardiac from noncardiac chest pain. Persistently increased values in individuals who present days after symptom onset support that myocardial damage has occurred. Outside of acute care, high-sensitivity troponin I supports cardiovascular risk stratification by detecting very low concentrations and short-term changes over time. The assay is incorporated into national and European cardiology guidance as an adjunctive marker for evaluating the risk of cardiovascular disease.

Troponins are regulatory proteins in striated muscle composed of three subunits—troponin C, I, and T—that coordinate contraction. Cardiac-specific troponin I (cTn I) and troponin T (cTn T) are confined to myocardium and are present at minimal concentrations in the circulation under physiologic conditions. Disruption of cardiomyocytes releases these proteins into blood, and circulating levels generally reflect the extent of myocardial damage. Troponin I provides the greatest sensitivity and specificity for myocardial injury among commonly used biomarkers. After an infarction, concentrations typically begin to rise within 3–4 hours and may remain elevated for 10–14 days. High-sensitivity troponin I supports detection of both acute injury and chronic, low-grade cardiomyocyte damage. Persistently increased concentrations signify ongoing myocardial injury and are associated with a higher likelihood of subsequent acute cardiovascular events.